Vir Biotechnology, Inc. (VIR) Form 10-Q — Aug 5, 2026

$VIRForm 10-QFiled Aug 5, 2026, 5:20 PM ET0001628280-26-053549Original filing

Vir Biotechnology reported Q2 2026 revenue of $238.9 million and net income of $80.1 million ($0.48 basic EPS), a sharp swing from a $111.0 million net loss in the year-ago quarter. The profit was driven by recognition of the $239.3 million residual upfront payment from the Astellas collaboration that closed on April 15, 2026. The company ended the quarter with approximately $1.01 billion in cash, cash equivalents and investments and no debt, which management says funds operations for at least twelve months.

Key figures

Eps: $0.48 basic / $0.47 diluted Q2 2026 (vs -$0.80 Q2 2025)
Revenue: $238.9 million Q2 2026 (vs $1.2 million Q2 2025); $238.9 million six months 2026
Net Income: $80.1 million Q2 2026 net income (vs $111.0 million net loss Q2 2025); six-month net loss of $45.6 million (vs $231.9 million)
Total Debt: None outstanding as of June 30, 2026
Cash Position: approximately $1.01 billion in cash, cash equivalents and investments as of June 30, 2026 ($278.7 million cash and equivalents; $8.9 million restricted cash)
Shares Outstanding: 169215958
Rd expense q2 2026: $135.3 million (vs $97.5 million Q2 2025)
Accumulated deficit: $1.2 billion as of June 30, 2026
Sga expense q2 2026: $30.2 million
Atm capacity td cowen: $300.0 million (no shares sold; expires November 2026)
Sanofi payment q2 2026: $48.0 million (20% share of certain Astellas collaboration proceeds)
Astellas stock purchase: $75.0 million for 7,239,382 shares
Astellas upfront payment: $240.0 million
Follow on offering feb 2026: 20,294,117 shares at $8.50 per share; net proceeds approximately $162.2 million
Astellas potential milestones: up to $1.39 billion (or up to $1.62 billion under opt-out scenario)
Total lease payments expected: approximately $114.2 million through 2035
License collab revenue q2 2026: $238.9 million (primarily $239.3 million Astellas upfront recognition)
Contingent consideration fair value: $34.3 million (Humabs acquisition)
Net cash used in operating six months: $9.1 million (vs $198.3 million prior year)

Price after filing

1 day: 0.0%7 days: -2.3%30 days: +24.9%

Close on the filing date to close N calendar days later (from $9.17). Historical, not a forecast.

AI analysis

Red flags6 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.